DASH Prediction Score for Recurrent VTE

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years

حداقل ۳ — حداکثر ۲۴ • واحد: months

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
dash assessment
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk-2–1
  • Intermediate Risk2–2
  • High Risk3–6
Direct Clinical Answer

The DASH Prediction Score for Recurrent VTE calculates predicting likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Key inputs include d dimer positive. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.

Clinical Indication

The DASH Prediction Score for Recurrent VTE is indicated for bedside clinical practice to support Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Excludes VTE during pregnancy, puerperium, trauma, surgery, immobilization, or active cancer.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Original validation used vitamin K antagonists.

Formula & Variables:

DASH Score = (+2 if D-dimer positive) + (+1 if age ≤50 years) + (+1 if male) + (-2 if hormonal therapy in women)

Input Parameters

NameTypeRequiredDescription
d_dimer_positivestringYesPost-anticoagulation D-dimer result (measured approximately 1 month after stopping anticoagulation)
ageintegerYesPatient age in years(years)
sexstringYesPatient biological sex
hormonal_therapystringYesHormonal therapy use at time of initial VTE (applies to women only, select 'not_applicable' for men)
vte_typestringNoType of initial venous thromboembolism for clinical context
anticoagulation_durationintegerNoDuration of initial anticoagulation treatment in months(months)

Score Interpretation & Guidance

RangeStageDescription
-2–1Low RiskLow annual recurrence risk
2–2Intermediate RiskModerate annual recurrence risk
3–6High RiskHigh annual recurrence risk

Evidence-Based References (EBM)

  • Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-1025. doi: 10.1111/j.1538-7836.2012.04735.x.DOI: 10.1111/j.1538-7836.2012.04735.x
  • Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.DOI: 10.1016/j.chest.2015.11.026
  • Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.DOI: 10.1182/bloodadvances.2020001830
  • Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. doi: 10.1161/CIRCULATIONAHA.109.925214.DOI: 10.1161/CIRCULATIONAHA.109.925214

Related calculators